Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy. The reimbursement agreement comes as the National Institute for Health and Care Excellence issues guidance recommending Casgevy’s use in the NHS. It means that eligible SCD patients in England now have access to the therapy following the prior agreement for transfusion-dependent beta thalassemia patients announced last August.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex (VRTX) Secures FDA Approval for Highly-Awaited Non-Opioid Painkiller
- Closing Bell Movers: Atlassian up 19%, Apple gains 3% after results
- Vertex Pharmaceuticals announces FDA approval of Journavx
- Vertex Pharmaceuticals up 2% at $448 after FDA Journavx approval
- Vertex Pharmaceuticals’ non-opioid painkiller approved by FDA, Bloomberg says